Chemistry:NNC2215

From HandWiki

NNC2215 is a bioengineered glucose-sensitive insulin. The drug is designed by a team of Novo Nordisk researchers.[1]

NNC2215 can sense the glucose concentration presence in blood, through incorporation of a glucose binding molecule developed in the University of Bristol.[2] The protein's sensitivity is reduced when low concentration of glucose, thus reducing the risk of hypoglycemia.[3] In addition, it can effectively cover the risk of fluctuations of blood sugar levels.

The study was published on scientific journal Nature on October 16, 2024.[4] This study demonstrated the ability of protein engineering in future medicine and a major advancement in treatment capabilities.

Background

A glucose sensitive treatment method for diabetes has long been pursued by researchers since 1979.[5] Such a platform is expected to solve the problem of fluctuations of blood sugar levels. For diabetic patients, skipping a single meal can lead to hypoglycemia, a common complication which can lead to loss of consciousness or seizures.[6]

There have been several attempts to create such a medicine, with various levels of success.[7][8]

See also

References

  1. ↑ PhD, Jonathan D. Grinstein (2024-10-21). "Novo Nordisk Researchers Engineer Glucose-Sensitive Insulin Switch" (in en-US). https://www.insideprecisionmedicine.com/topics/translational-research/novo-nordisk-researchers-engineer-glucose-sensitive-insulin-switch/. 
  2. ↑ Tromans, Robert A.; Carter, Tom S.; Chabanne, Laurent; Crump, Matthew P.; Li, Hongyu; Matlock, Johnathan V.; Orchard, Michael G.; Davis, Anthony P. (2019). "A biomimetic receptor for glucose" (in en). Nature Chemistry 11 (1): 52–56. doi:10.1038/s41557-018-0155-z. ISSN 1755-4349. https://www.nature.com/articles/s41557-018-0155-z. 
  3. ↑ Kwon, Diana (2024-10-16). "'Smart' insulin prevents diabetic highs — and deadly lows" (in en). Nature. doi:10.1038/d41586-024-03357-7. PMID 39414970. https://www.nature.com/articles/d41586-024-03357-7. 
  4. ↑ Hoeg-Jensen, Thomas; Kruse, Thomas; Brand, Christian L.; Sturis, Jeppe; Fledelius, Christian; Nielsen, Peter K.; Nishimura, Erica; Madsen, Alice R. et al. (16 October 2024). "Glucose-sensitive insulin with attenuation of hypoglycaemia" (in en). Nature 634 (8035): 944–951. doi:10.1038/s41586-024-08042-3. ISSN 1476-4687. PMID 39415004. Bibcode: 2024Natur.634..944H. 
  5. ↑ Brownlee, Michael; Cerami, Anthony (1979-12-07). "A Glucose-Controlled Insulin-Delivery System: Semisynthetic Insulin Bound to Lectin". Science 206 (4423): 1190–1191. doi:10.1126/science.505005. PMID 505005. Bibcode: 1979Sci...206.1190B. https://www.science.org/doi/10.1126/science.505005. 
  6. ↑ "Low Blood Glucose (Hypoglycemia) - NIDDK" (in en-US). https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia. 
  7. ↑ Jarosinski, Mark A; Chen, Yen-Shan; Varas, Nicolás; Dhayalan, Balamurugan; Chatterjee, Deepak; Weiss, Michael A (2022-04-01). "New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals". The Journal of Clinical Endocrinology & Metabolism 107 (4): 909–928. doi:10.1210/clinem/dgab849. ISSN 0021-972X. PMID 34850005. 
  8. ↑ Liu, Yun; Wang, Shiqi; Wang, Zejun; Yu, Jicheng; Wang, Jinqiang; Buse, John B.; Gu, Zhen (2024-06-10). "Recent Progress in Glucose-Responsive Insulin". Diabetes 73 (9): 1377–1388. doi:10.2337/dbi23-0028. ISSN 0012-1797. PMID 38857114. https://diabetesjournals.org/diabetes/article-abstract/73/9/1377/156832/Recent-Progress-in-Glucose-Responsive-Insulin?redirectedFrom=fulltext. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:NNC2215&oldid=4309779"